Xilio Therapeutics, Inc. (XLO) Total Assets by Year
Xilio Therapeutics, Inc. closed fiscal year 2025 with $154.7M in total assets, $119.4M in total liabilities and $35.3M in shareholder equity. This represents an increase of 117.6% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Xilio Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
XLO Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $154.7M+117.6% | $71.1M+16.7% | $60.9M-56.2% | $139.2M-36.2% | $218.1M+500.4% | $36.3M |
| Total Liabilities | $119.4M+123.3% | $53.5M+121.9% | $24.1M-28.1% | $33.5M+2.7% | $32.6M-72.7% | $119.6M |
| Total Equity | $35.3M+100.4% | $17.6M-52.2% | $36.8M-65.1% | $105.6M-43.0% | $185.4M+322.6% | -$83.3M |
XLO Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $154.3M+15.3% | $163.5M+57.6% | $154.7M+117.6% | $133.7M+79.1% | $133.8M+48.9% | $103.7M+25.6% | $71.1M+16.7% | $74.7M-4.1% | $89.9M-2.7% | $82.6M-25.9% | $60.9M-56.2% | $77.8M-50.5% |
| Total Liabilities | $82.0M-35.3% | $90.9M-2.2% | $119.4M+123.3% | $141.8M+164.1% | $126.7M+124.5% | $93.0M+63.6% | $53.5M+121.9% | $53.7M+111.8% | $56.5M+126.0% | $56.8M+112.8% | $24.1M-28.1% | $25.3M-18.5% |
| Total Equity | $72.3M+922.3% | $72.5M+578.0% | $35.3M+100.4% | -$8.1M-138.6% | $7.1M-78.8% | $10.7M-58.5% | $17.6M-52.2% | $21.0M-60.0% | $33.4M-50.4% | $25.8M-69.6% | $36.8M-65.1% | $52.5M-58.4% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Xilio Therapeutics, Inc. financials
Frequently Asked Questions
What was Xilio Therapeutics, Inc.'s total assets in fiscal year 2025?
Xilio Therapeutics, Inc. closed fiscal year 2025 with $154.7M in total assets, $119.4M in total liabilities and $35.3M in shareholder equity.
How fast is Xilio Therapeutics, Inc.'s total assets growing?
Xilio Therapeutics, Inc. (XLO) total assets rose by 117.6% year over year, from $71.1M to $154.7M in fiscal year 2025.
How has Xilio Therapeutics, Inc.'s total assets changed over the years?
Across the 6 fiscal years this page covers, Xilio Therapeutics, Inc. (XLO) total assets went from $36.3M in fiscal year 2020 to $154.7M in fiscal year 2025.
What was Xilio Therapeutics, Inc.'s total assets in the most recent quarter?
Xilio Therapeutics, Inc. (XLO) reported $154.3M in total assets in Q2 2026. This represents an increase of 15.3% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Xilio Therapeutics, Inc. (XLO) reported on that line in every period on record.